Premenstrual dysphoric disorder

Neurosteroid Effects in the Central Nervous System: The Role of the GABA-A Receptor

Volumn , Issue , 2003, Pages 291-304

  Sundström Poromaa, Inger ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885695682     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (90)

1. Sveindottir, H. and Bäckström, T., Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives, Acta Obstet. Gynecol. Scand., 79, 405, 2000.
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., U.S. Department of Health and Human Services, Washington D.C., 1994, p. 714.
3. Bloch, M., Schmidt, P.J., and Rubinow, D.R., Premenstrual syndrome: evidence for symptom stability across cycles, Am. J. Psychiatry, 154, 1741, 1997.
4. Hurt, S.W. et al., Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints, Am. J. Psychiatry, 149, 525, 1992.
5. Hammarbäck, S. and Bäckström, T., A demographic study in subgroups of women seeking help for premenstrual syndrome, Acta Obstet. Gynecol. Scand., 68, 247, 1989.
6. Wittchen, H.U. et al., Prevalence, incidence and stability of premenstrual dysphoric disorder in the community, Psychol. Med., 32, 119, 2002.
7. Andersch, B. et al., Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population, J. Psycosom. Obstet. Gynaecol., 5, 39, 1986.
8. Hammarbäck, S., Damber, J.E., and Bäckström, T., Relationship between symptom severity and hormone changes in women with premenstrual syndrome, J. Clin. Endocrinol. Metab., 68, 125, 1989.
9. Bailey, J.W. and Cohen, L.S., Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome, J. Womens Health Gend. Based Med., 8, 1181, 1999.
10. Ekholm, U.B. and Bäckström, T., Influence of premenstrual syndrome on family, social life, and work performance, Int. J. Health Serv., 24, 629, 1994.
11. Fava, M., Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder, J. Anxiety Disord., 6, 325, 1992.
12. Steege, J.F. et al., Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome, Am. J. Obstet. Gynecol., 167, 168, 1992.
13. Baca-Garcia, E. et al., Menstrual cycle and profiles of suicidal behaviour, Acta Psychiatr. Scand., 97, 32, 1998.
14. Severino, S.K., Late luteal phase dysphoric disorder: a scientific puzzle, Med. Hypotheses, 41, 229, 1993.
15. Pearlstein, T.B. et al., Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder, J. Affect. Disord., 20, 129, 1990.
16. Breaux, C., Hartlage, S., and Gehlert, S., Relationships of premenstrual dysphoric disorder to major depression and anxiety disorders: a re-examination, J. Psychosom. Obstet. Gynaecol., 21, 17, 2000.
17. Graze, K.K., Nee, J., and Endicott, J., Premenstrual depression predicts future major depressive disorder, Acta Psychiatr. Scand., 81, 201, 1990.
18. Hartlage, S.A., Arduino, K.E., and Gehlert, S., Premenstrual dysphoric disorder and risk for major depressive disorder: a preliminary study, J. Clin. Psychol., 57, 1571, 2001.
19. Wyatt, K.M., Dimmock, P.W., and O’Brien, P.M., Selective serotonin reuptake inhibitors for premenstrual syndrome, Cochrane Database Syst. Rev., CD001396, 2002 (Cochrane review).
20. Endicott, J. et al., Is premenstrual dysphoric disorder a distinct clinical entity? J. Womens Health Gend. Based Med., 8, 663, 1999.
21. Hammarbäck, S. and Bäckström, T., Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo, Acta Obstet. Gynecol. Scand., 67, 159, 1988.
22. Hammarbäck, S., Ekholm, U.B., and Bäckström, T., Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome, Acta Endocrinol. (Copenhagen), 125, 132, 1991.
23. Mortola, J.F., Girton, L., and Fischer, U., Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin, J. Clin. Endocrinol. Metab., 72, 252A, 1991.
24. Brown, C.S. et al., Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial, Obstet. Gynecol., 84, 779, 1994.
25. Leather, A.T. et al., The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study, Gynecol. Endocrinol., 13, 48, 1999.
26. Mezrow, G. et al., Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome, Fertil. Steril., 62, 932, 1994.
27. Sundström, I. et al., Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen, Acta Obstet. Gynecol. Scand., 78, 891, 1999.
28. Bäckström, T. et al., Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome, Psychosom. Med., 45, 503, 1983.
29. Rubinow, D.R. et al., Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects, Am. J. Obstet. Gynecol., 158, 5, 1988.
30. Rabin, D.S. et al., Hypothalamic-pituitary-adrenal function in patients with the premenstrual syndrome, J. Clin. Endocrinol. Metab., 71, 1158, 1990.
31. Redei, E. and Freeman, E.W., Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms, Psychoneuroendocrinology, 20, 259, 1995.
32. Reame, N.E., Marshall, J.C., and Kelch, R.P., Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle, Psychoneuroendocrinology, 17, 205, 1992.
33. Björn, I. et al., The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy, Gynecol. Endocrinol., 16, 1, 2002.
34. Björn, I. et al., Negative mood changes during hormone replacement therapy: a comparison between two progestogens, Am. J. Obstet. Gynecol., 183, 1419, 2000.
35. Hammarbäck, S. et al., Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy, Acta Obstet. Gynecol. Scand., 64, 393, 1985.
36. Seippel, L. and Bäckström, T., Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome, J. Clin. Endocrinol. Metab., 83, 1988, 1998.
37. Dhar, V. and Murphy, B.E., The premenstrual syndrome and its treatment, J. Steroid Biochem. Mol. Biol., 39, 275, 1991.
38. Straneva, P.A. et al., Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder, Health Psychol., 21, 358, 2002.
39. Eriksson, E. et al., The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome, Neuropsychopharmacology, 12, 167, 1995.
40. Halbreich, U. and Tworek, H., Altered serotonergic activity in women with dysphoric premenstrual syndromes, Int. J. Psychiatry Med., 23, 1, 1993.
41. Parry, B.L., The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications, CNS Drugs, 15, 277, 2001.
42. Halbreich, U. et al., Increased imidazoline and alpha 2 adrenergic binding in platelets of women with dysphoric premenstrual syndromes, Biol. Psychiatry, 34, 676, 1993.
43. Epperson, C.N. et al., Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study, Arch. Gen. Psychiatry, 59, 851, 2002.
44. Halbreich, U. et al., Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder, Am. J. Psychiatry, 153, 718, 1996.
45. Sundström, I., Ashbrook, D., and Bäckström, T., Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study, Psychoneuroendocrinology, 22, 25, 1997.
46. Sundström, I., Nyberg, S., and Bäckström, T., Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects, Neuropsychopharmacology, 17, 370, 1997.
47. Evans, S.M. et al., Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam, Neuropsychopharmacology, 19, 499, 1998.
48. Schmidt, P.J., Grover, G.N., and Rubinow, D.R. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial, Arch. Gen. Psychiatry, 50, 467, 1993.
49. Smith, S. et al., Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial, Obstet. Gynecol., 70, 37, 1987.
50. Freeman, E.W. et al., A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome, JAMA, 274, 51, 1995.
51. Le Melledo, J.M. et al., Response to flumazenil in women with premenstrual dysphoric disorder, Am. J. Psychiatry, 157, 821, 2000.
52. Nutt, D.J. et al., Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder, Arch. Gen. Psychiatry, 47, 917, 1990.
53. Baulieu, E.E., Neurosteroids: a new function in the brain, Biol. Cell, 71, 3, 1991.
54. Stoffel-Wagner, B., Neurosteroid metabolism in the human brain, Eur. J. Endocrinol., 145, 669, 2001.
55. Genazzani, A.R. et al., Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences, J. Clin. Endocrinol. Metab., 83, 2099, 1998.
56. Bäckström, T. et al., The human corpus luteum secretes 5 α-pregnane-3,20-dione, Acta Endocrinol. (Copenhagen), 111, 116, 1986.
57. Paul, S.M. and Purdy, R.H., Neuroactive steroids, FASEB J., 6, 2311, 1992.
58. Wang, M. et al., Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one, J. Clin. Endocrinol. Metab., 81, 1076, 1996.
59. Bixo, M. et al., Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnane-20-one in specific regions of the human female brain in different endocrine states, Brain Res., 764, 173, 1997.
60. Chan, A.F. et al., Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486, Obstet. Gynecol., 84, 1001, 1994.
61. Schmidt, P.J. et al., Lack of effect of induced menses on symptoms in women with premenstrual syndrome, N. Engl. J. Med., 324, 1174, 1991.
62. Sundström, I. and Bäckström, T., Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects, Biol. Psychiatry, 44, 755, 1998.
63. Schmidt, P.J. et al., Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects, J. Clin. Endocrinol. Metab., 79, 1256, 1994.
64. Bicikova, M. et al., Allopregnanolone in women with premenstrual syndrome, Horm. Metab. Res., 30, 227, 1998.
65. Rapkin, A.J. et al., Progesterone metabolite allopregnanolone in women with premenstrual syndrome, Obstet. Gynecol., 90, 709, 1997.
66. Monteleone, P. et al., Allopregnanolone concentrations and premenstrual syndrome, Eur. J. Endocrinol., 142, 269, 2000.
67. Girdler, S.S. et al., Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder, Biol. Psychiatry, 49, 788, 2001.
68. Bitran, D. et al., Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat, Psychopharmacology, 151, 64, 2000.
69. Daly, R.C. et al., Effects of gonadal steroids on peripheral benzodiazepine receptor density in women with PMS and controls, Psychoneuroendocrinology, 26, 539, 2001.
70. Schmidt, P.J. et al., Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome, N. Engl. J. Med., 338, 209, 1998.
71. Bäckström, T. et al., The role of hormones and hormonal treatments in premenstrual syndrome, Drugs, CNS, 17, 325, 2003.
72. Bitran, D., Purdy, R.H., and Kellogg, C.K., Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function, Pharmacol. Biochem. Behav., 45, 423, 1993.
73. Akwa, Y. et al., The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat, Behav. Brain. Res., 106, 119, 1999.
74. Wieland, S. et al., Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one, Brain Res., 565, 263, 1991.
75. Gulinello, M. et al., Short-term exposure to a neuroactive steroid increases α4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat, Brain Res., 910, 55, 2001.
76. de Lignieres, B., Dennerstein, L. and Bäckström, T., Influence of route of administration on progesterone metabolism, Maturitas, 21, 251, 1995.
77. Vanselow, W. et al., Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration, J. Psychosom. Obstet. Gynaecol., 17, 29, 1996.
78. Freeman, E.W. et al., Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers, Neuroendocrinology, 58, 478, 1993.
79. Uzunova, V. et al., Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine, Proc. Natl. Acad. Sci. U.S.A., 95, 3239, 1998.
80. Romeo, E. et al., Effects of antidepressant treatment on neuroactive steroids in major depression, Am. J. Psychiatry, 155, 910, 1998.
81. Freeman, E.W. et al., Allopregnanolone levels and symptom improvement in severe premenstrual syndrome, J. Clin. Psychopharmacol., 22, 516, 2002.
82. Gallo, M.A. and Smith, S.S., Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety, Pharmacol. Biochem. Behav., 46, 897, 1993.
83. A receptor α4 subunit in association with increased anxiety, J. Neurosci., 18, 5275, 1998.
84. Smith, S.S. et al., GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid, Nature, 392, 926, 1998.
85. Moran, M.H., Goldberg, M., and Smith, S.S., Progesterone withdrawal. II. Insensitivity to the sedative effects of a benzodiazepine, Brain Res., 807, 91, 1998.
86. Sundström, I. et al., Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects, Neuroendocrinology, 67, 126, 1998.
87. Uzunov, D.P. et al., Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography, Proc. Natl. Acad. Sci. U.S.A., 93, 12599, 1996.
88. Griffin, L.D. and Mellon, S.H., Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes, Proc. Natl. Acad. Sci. U.S.A., 96, 13512, 1999.
89. Sundström, I. and Bäckström, T., Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial, Psychoneuroendocrinology, 23, 73, 1998.
90. Rasgon, N. et al., Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome, Eur. J. Endocrinol., 145, 25, 2001.